- Wedbush has added Compass Therapeutics ( NASDAQ: CMPX ) to its Best Ideas List based on the company's lead asset CTX-009, a bispecific antibody for biliary tract cancer and colorectal cancer
- The firm has an outperform rating and an $8 price target (~110% upside based on Monday's close).
- Shares are up 12% in Tuesday morning trading.
- Analyst Robert Driscoll said that CTX-009 is in phase 2/3 for biliary tract cancer in combination with paclitaxel and in phase 2 as a monotherapy for colorectal cancer. He added the company is planning a phase 2 study in ovarian cancer in the second half of the year.
- Driscoll noted that a recent data update for CTX-009 in biliary tract cancer showed impressive results.
- He said that a recent selloff in shares may have been over concern with the candidate's side effect profile, but he sees a high probability of success for the biliary tract cancer trial.
- Seeking Alpha's Quant Rating sees Compass ( CMPS ) with high marks for momentum and growth .
For further details see:
Compass Therapeutics added to Wedbush Best Ideas List on lead cancer candidate